TrACER: Trial Assessing CSF prescribing Effectiveness and Risk

Study Description: Some drugs used to treat cancer raise a patient's risk of febrile neutropenia. Febrile neutropenia is a condition that involves a fever and a low number of neutrophils (a type of white blood cell) in the blood. Having a low number of neutrophils puts a patient at risk of infection. Colony-stimulating factors (CSFs) are medications sometimes given to patients getting cancer treatment to prevent or treat febrile neutropenia. CSFs are given as an injection under the skin or into a vein. The purpose of this study is to determine if an automated system prescribing CSFs will help doctors use CSF when it is needed and not use it when it is not needed. The study also wants to learn about the benfits and risks of using CSF with cancer treatment drugs that have a moderate (not high and not low) risk of febrile neutropenia.

Contact for Enrollment


    Submit Information Online

Principal Investigator: Sharad Ghamande

Eligibility Criteria: -18 years of age or older. - Current diagnosis of breast, non-small cell lung cancer, or colorectal cancer. - Metastatic or non-metastatic - Must be planning to receive chemotherapy and/or radiation therapy.

Compensation: No, subjects will not be compensated.


Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.